Vanguard Global Advisers
SABS icon

Vanguard Global Advisers’s SAB Biotherapeutics SABS Stock Holding History

Vanguard Global Advisers’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.2K Hold
11,852
– – ﹤0.01% 3099
2026
Q1 		$45.4K Buy
+11,852
New +$47.3K ﹤0.01% 3067

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Global Advisers's SABS Position: Q2 2026 in Review

Vanguard Global Advisers held its SAB Biotherapeutics (SABS) position steady in Q2 2026 at 11,852 shares worth $46.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3099.

Vanguard Global Advisers first reported a position in SABS in Q1 2026 and has held it in 2 quarters since. 85 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Vanguard Global Advisers held 11,852 shares of SAB Biotherapeutics worth $46.2K as of Q2 2026.
  • Vanguard Global Advisers left its SAB Biotherapeutics share count unchanged in Q2 2026.
  • SAB Biotherapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3099 holding.
  • Vanguard Global Advisers first reported a position in SAB Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 85 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.